Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial

医学 甲基强的松龙 中止 外科 随机对照试验 人口 麻醉 环境卫生
作者
George J. Kahaly,Michaela Riedl,J. König,Susanne Pitz,Katharina A. Ponto,Tanja Diana,Elena Kampmann,E. W. Kolbe,Anja Eckstein,Lars C. Moeller,Dagmar Führer,Mario Salvi,Nicola Currò,Irene Campi,Danila Covelli,Marenza Leo,Michele Marinò,Francesca Menconi,Claudio Marcocci,Luigi Bartalena
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:6 (4): 287-298 被引量:174
标识
DOI:10.1016/s2213-8587(18)30020-2
摘要

Summary

Background

European guidelines recommend intravenous methylprednisolone as first-line treatment for active and severe Graves' orbitopathy; however, it is common for patients to have no response or have relapse after discontinuation of treatment. We aimed to compare the efficacy and safety of add-on mycophenolate to methylprednisolone in comparison with methylprednisolone alone in patients with moderate-to-severe Graves' orbitopathy.

Methods

MINGO was an observer-masked, multicentre, block-randomised, centre-stratified trial done in two centres in Germany and two in Italy. Patients with active moderate-to-severe Graves' orbitopathy were randomly assigned to receive intravenous methylprednisolone (500 mg once per week for 6 weeks followed by 250 mg per week for 6 weeks) either alone or with mycophenolate (one 360 mg tablet twice per day for 24 weeks). The prespecified primary endpoints were rate of response (reduction of at least two parameters of a composite ophthalmic index [eyelid swelling, clinical activity score, proptosis, lid width, diplopia, and eye muscle motility] without deterioration in any other parameter) at 12 weeks and rate of relapse (a worsening of symptoms that occurred after a response) at 24 and 36 weeks. Rates of response at week 24 and sustained response at week 36 were added as post-hoc outcomes. Prespecified primary outcomes and post-hoc outcomes were assessed in the modified intention-to-treat population (defined as all patients assigned to treatment who received at least one infusion of methylprednisolone, when outcome data were available), and safety was assessed in all patients who received at least one dose of study drug. This trial is registered with the EU Clinical Trials Register, EUDRACT number 2008-002123-93.

Findings

164 patients were enrolled and randomised between Nov 29, 2009, and July 31, 2015. 81 were randomly assigned to receive methylprednisolone alone and 83 to receive methylprednisolone with mycophenolate. In the intention-to-treat population at 12 weeks, responses were observed in 36 (49%) of 73 patients in the monotherapy group and 48 (63%) of 76 patients in the combination group, giving an odds ratio (OR) of 1·76 (95% CI 0·92–3·39, p=0·089). At week 24, 38 (53%) of 72 patients remaining in the monotherapy group and 53 (71%) of 75 patients remaining in the combination therapy group had responded to treatment (2·16, 1·09–4·25, p=0·026). At week 24, relapse occurred in four (11%) of 38 patients in the monotherapy group and four (8%) of 53 patients in the combination group (OR 0·71, 0·17–3·03, p=0·72). At week 36, relapse occurred in an additional three (8%) patients in the monotherapy group and two (4%) patients in the combination group (0·65, 0·12–3·44, p=0·61). At week 36, 31 (46%) of 68 patients in the monotherapy group and 49 (67%) of 73 patients in the combination group had a sustained response (OR 2·44, 1·23–4·82, p=0·011). 23 patients had 24 serious adverse events, with 11 events in ten patients in the combination group and 13 events in 13 patients in the monotherapy group. Mild and moderate (grade 1–2) drug-related adverse events occurred in 16 (20%) of 81 patients receiving monotherapy and 21 (25%) of 83 patients receiving combination therapy (p=0·48).

Interpretation

Although no significant difference was seen in the rate of response at 12 weeks or rate of relapse at 24 and 36 weeks, post-hoc analysis suggested that addition of mycophenolate to treatment with methylprednisolone improved rate of response to therapy by 24 weeks in patients with active and moderate-to-severe Graves' orbitopathy.

Funding

Novartis, Germany.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
四辈发布了新的文献求助10
1秒前
3秒前
跳跃的冬灵关注了科研通微信公众号
3秒前
3秒前
4秒前
4秒前
星辰大海应助宫_采纳,获得10
5秒前
吉星发布了新的文献求助10
7秒前
有爱便神经完成签到,获得积分10
7秒前
大模型应助科研通管家采纳,获得10
7秒前
在水一方应助壮观的擎采纳,获得10
7秒前
田様应助科研通管家采纳,获得10
7秒前
NexusExplorer应助科研通管家采纳,获得10
7秒前
8秒前
烟花应助科研通管家采纳,获得10
8秒前
8秒前
8秒前
8秒前
8秒前
8秒前
8秒前
天真皓轩发布了新的文献求助10
8秒前
8秒前
8秒前
8秒前
英俊的铭应助重要衬衫采纳,获得10
9秒前
科研通AI2S应助犹豫的甜瓜采纳,获得10
12秒前
xuan完成签到,获得积分10
12秒前
老实的美女完成签到,获得积分10
14秒前
兜兜发布了新的文献求助10
14秒前
wynter完成签到,获得积分10
18秒前
19秒前
隐形曼青应助徐狗馨采纳,获得10
20秒前
20秒前
fancynancy应助duxh123采纳,获得20
21秒前
23秒前
23秒前
24秒前
Wang发布了新的文献求助10
24秒前
25秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3959633
求助须知:如何正确求助?哪些是违规求助? 3505879
关于积分的说明 11126688
捐赠科研通 3237840
什么是DOI,文献DOI怎么找? 1789380
邀请新用户注册赠送积分活动 871691
科研通“疑难数据库(出版商)”最低求助积分说明 802963